Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 15/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | AHCY | P23526 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297471 | 0.85 | ADK (0.65) | ADKPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL90988 | 0.84 | PI4KA (0.66) | ADKPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL60676 | 0.84 | PI4KA (0.66) | ADKPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL67726 | 0.84 | PI4KA (0.66) | ADKPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23120996 | 0.82 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL13623625 | 0.82 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL13610771 | 0.82 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL13435086 | 0.82 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL19953837 | 0.82 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL16141172 | 0.82 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | UNIV MINNESOTA (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2023230061-A2 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | NSUN2, SARS1, RNMT | ADK 556/4885PI4KA 2862/4885PI4K2B 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.